COMPARE · Data as of August 24, 2026
RDNT vs RMD
Verdict: Side-by-side breakdown using the Bull Rankings model. RDNT scored 56.1, RMD scored 81.1 — RMD leads.
Compare another set
RDNT
RadNet, Inc.
56.1
$74.69 · $5.9B
fundamentals as of
Score gap
25.0
RMD leads
RMD
ResMed Inc.
81.1
$232.45 · $33.5B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- Fastest growthRDNT+18.9%
- Strongest balance sheetRMD0.13
- Highest qualityRMD90 / 100
- Largest discount to fair valueRMD-4%
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
RDNT
stronger →← stronger
RMD
35
Qualityreturns · margins · balance sheet
90
86
Growthrevenue & earnings expansion
82
58
Valuevaluation vs sector peers
72
RMD is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
RDNT
RMD
$236mC
FCF
$1.6bC+
+18.9%B+
Rev
+9.9%B
1.57C
D/E
0.13B+
2.6xB+
P/S
—
0.96B+
PEG
1.34B
—
P/E
22.2xB+
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
RDNT
RMD
39% above
Price vs fair valuelower is cheaper
4% below
~24%/yr
Growth the price implies10-yr FCF · lower = less priced in
~5%/yr
-45%
1-yr DCF upside
-4%
-28%
5-yr DCF upside
+4%
+5%
10-yr DCF upside
+18%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
RDNT
Why this score
- Diluting shareholders
RMD
Why this score
- Raising its dividend
- Durable high returns
The companies
RDNTRadNet, Inc.
Why now
Diagnostics & Research · market cap $5.9b. 13% off the 52-week high of $85.84. Revenue growing +19%, comfortably above the S&P median. PEG 0.96 — paying under fair value for the growth rate. 8 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $92.88 (implying +24% upside).
Moat
Turnaround / out-of-favor name — GAAP-unprofitable for now, so the durability case is forward-looking: it rests on a recovery (margin normalization, a cyclical upturn or restructuring) or an un-monetized asset (IP / network effects / first-mover position) rather than on current reported results.
Risk
Currently unprofitable (margin -0.9%) — path to GAAP profitability is the core thesis risk. ROE -2% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
RMDResMed Inc.
Why now
Medical Instruments & Supplies · market cap $33.5b. 19% off the 52-week high of $286.91. 16 sell-side analysts rate this a Buy with a mean 1-yr target of $245.50 (implying +6% upside).
Moat
Net margin 27% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 23% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 108% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where RDNT and RMD diverge
On the headline score the gap is 25.0 points in favor of RMD. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- QualityRDNT 35.2 · RMD 90.4RMD +55.2
- ValueRDNT 58.1 · RMD 72.2RMD +14.1
- GrowthRDNT 86.5 · RMD 81.6RDNT +4.9
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.